Matsuda T, Muromoto R, Sekine Y, Togi S, Kitai Y, Kon S, Oritani K. Signal transducer and activator of transcription 3 regulation by novel binding partners. World J Biol Chem 2015; 6(4): 324-332 [PMID: 26629315 DOI: 10.4331/wjbc.v6.i4.324]
Corresponding Author of This Article
Tadashi Matsuda, PhD, Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-Ku Kita 12 Nishi 6, Sapporo 060-0812, Japan. tmatsuda@pharm.hokudai.ac.jp
Research Domain of This Article
Biochemistry & Molecular Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Matsuda T, Muromoto R, Sekine Y, Togi S, Kitai Y, Kon S, Oritani K. Signal transducer and activator of transcription 3 regulation by novel binding partners. World J Biol Chem 2015; 6(4): 324-332 [PMID: 26629315 DOI: 10.4331/wjbc.v6.i4.324]
Tadashi Matsuda, Ryuta Muromoto, Yuichi Sekine, Sumihito Togi, Yuichi Kitai, Shigeyuki Kon, Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Hokkaido 060-0812, Japan
Kenji Oritani, Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan
Author contributions: All authors contributed to this paper.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Tadashi Matsuda, PhD, Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-Ku Kita 12 Nishi 6, Sapporo 060-0812, Japan. tmatsuda@pharm.hokudai.ac.jp
Telephone: +81-11-7063243 Fax: +81-11-7064990
Received: January 20, 2015 Peer-review started: January 20, 2015 First decision: April 10, 2015 Revised: August 24, 2015 Accepted: September 1, 2015 Article in press: September 2, 2015 Published online: November 26, 2015 Processing time: 306 Days and 20.6 Hours
Core Tip
Core tip: Signal transducer and activator of transcription 3 (STAT3) has been proposed its physiological and pathological significance in malignant and inflammatory diseases; therefore, the targeting of the STAT3 pathways is likely to be suitable for clinical application. In this review, we introduced novel regulatory molecules of STAT3 binding partners, such as DAXX, zipper-interacting protein kinase, Krüppel-associated box-associated protein 1, Y14, PDZ and LIM domain 2 and signal transducing adaptor protein-2. These proteins positively or negatively regulate critical steps of STAT3-mediated signals via individually unique mechanism. We hope that the information described here will help to develop a new strategy to clinically control the STAT3 activities.
